parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.07 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in esophageal apical cells	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 4063

ZNF780A in dopamine neurons, braak+0.49 (p 0.177) → +0.19 (p 0.630)receipt 4070
ZNF780A in microglia, braak+0.76 (p 0.018) → -0.03 (p 0.946)receipt 4069

receipt 4070: ZNF780A in dopamine neurons, braak

power: full sample +0.35 (p 0.156, n 18), 95% CI -0.14 to +0.70. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.29 (p 0.239, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.33 (p 0.179, n 18). could be the mix.
skeptic: leave-one-out range +0.26 to +0.50, sign flips 0; without severely affected donors +0.35 (p 0.156, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ZNF780A in dopamine neurons.

case closed: nothing better to follow up.

receipt 4069: ZNF780A in microglia, braak

power: full sample +0.17 (p 0.509, n 18), 95% CI -0.33 to +0.59. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.16 (p 0.538, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.16 (p 0.532, n 18). could be the mix.
skeptic: leave-one-out range +0.06 to +0.31, sign flips 0; without severely affected donors +0.17 (p 0.509, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ZNF780A in microglia.

case closed: nothing better to follow up.

loading the receipts